Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

NASDAQ:KYMR

Kymera Therapeutics, Inc.

Last Close

49.86

08/11 21:00

Market Cap

2.22B

Beta: 1.72

Volume Today

289.99K

Avg: 454.77K

PE Ratio

−12.25

PFCF: −11.64

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics